

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



ASKA Launches Oral Contraceptive Slinda® 28 Tablets in Japan

TOKYO, June 30, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced today that ASKA launched the oral contraceptive, Slinda® 28 Tablets (generic name: drospirenone), in Japan on June 30, 2025.

As announced in the Company's press release dated May 19, 2025, titled “ASKA Obtains Manufacturing and Marketing Approval for Oral Contraceptive Slinda® 28 Tablets in Japan,” this drug is a progestogen-only oral contraceptive (POP: Progestogen-Only Pill) containing drospirenone, which was introduced and developed by ASKA in Japan with the aim of expanding women's health options. In January 2020, ASKA acquired exclusive rights to develop and market the Product for the territories of Japan and Republic of Korea from Insud Pharma (Head Office: Madrid, Spain).

Currently, the Combined Oral Contraceptive Pill (COCP), which contains two types of female hormones, synthetic estrogen and progestin, is used as an oral contraceptive in Japan. This drug, a progestogen-only pill (POP) containing drospirenone, is approved in 62 foreign countries (as of January 2025). According to the World Health Organization guidelines, POP carries a lower risk of venous thromboembolism than COCP and is more highly recommended than COCP for smokers, obese women, women with hypertension or valvular disease, or those with a history of deep vein thrombosis or pulmonary embolism.

ASKA will continue to address women's health issues in earnest and contribute to society by providing pharmaceutical products that help solve problems at every stage of life.

The impact of this matter on business results has been factored into the Forecast of consolidated financial results for FY2025.

Overview of Slinda® 28 Tablets

Product name: Slinda® 28 Tablets

Generic name: Drospirenone

Indication: Contraceptive

Dosage and Administration: One tablet per day should be taken every day for 28 consecutive days at

about the same time of the day in accordance with the specified order starting with a white tablet.

These 28 days will constitute one administration cycle with the next cycle of tablets being taken from the 29th day, and the same being repeated thereafter.

About Insud Pharma

Insud Pharma (<https://www.insudpharma.com/en/>) is a leading Spanish company with a track record in the pharmaceutical and healthcare industry spanning over 45 years. With 9,000 employees worldwide, Insud Pharma's contribution to global public health is enormous, thanks to the medicines and APIs developed and manufactured at its three highly synergic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: kouhou@aska-pharma.co.jp